Identification of NMS‐873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

[1]  F. Hayden,et al.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents , 2018, The New England journal of medicine.

[2]  Chunlong Ma,et al.  Discovery of dapivirine, a nonnucleoside HIV‐1 reverse transcriptase inhibitor, as a broad‐spectrum antiviral against both influenza A and B viruses , 2017, Antiviral research.

[3]  Chunlong Ma,et al.  Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral , 2017, International journal of molecular sciences.

[4]  R. Webster,et al.  Can we beat influenza? , 2017, Science.

[5]  S. Lal,et al.  The influenza A virus matrix protein 2 undergoes retrograde transport from the endoplasmic reticulum into the cytoplasm and bypasses cytoplasmic proteasomal degradation , 2017, Archives of Virology.

[6]  Y. Orba,et al.  Valosin-containing protein (VCP/p97) plays a role in the replication of West Nile virus , 2016, Virus Research.

[7]  Chunlong Ma,et al.  Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance. , 2016, Antiviral research.

[8]  F. Bard,et al.  Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes , 2015, Journal of Virology.

[9]  Chunlong Ma,et al.  Recent progress in designing inhibitors that target the drug‐resistant M2 proton channels from the influenza A viruses , 2015, Biopolymers.

[10]  Tiago J. S. Lopes,et al.  Influenza virus-host interactome screen as a platform for antiviral drug development. , 2014, Cell host & microbe.

[11]  A. Hurt.  The epidemiology and spread of drug resistant human influenza viruses. , 2014, Current opinion in virology.

[12]  H. Meyer,et al.  The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis , 2014, Journal of Cell Science.

[13]  G. Palù,et al.  Antiviral strategies against influenza virus: towards new therapeutic approaches , 2014, Cellular and Molecular Life Sciences.

[14]  S. Cherry,et al.  Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry. , 2013, Cell reports.

[15]  E. Fodor,et al.  Transport of the Influenza Virus Genome from Nucleus to Nucleus , 2013, Viruses.

[16]  A. Isacchi,et al.  Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. , 2013, Nature chemical biology.

[17]  R. Lamb,et al.  Textbook of Influenza , 2013 .

[18]  F. Hayden,et al.  Oseltamivir resistance during treatment of H7N9 infection , 2013, The Lancet.

[19]  T. Wakita,et al.  Valosin-Containing Protein (VCP/p97) Is Required for Poliovirus Replication and Is Involved in Cellular Protein Secretion Pathway in Poliovirus Infection , 2012, Journal of Virology.

[20]  M. Bug,et al.  Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system , 2012, Nature Cell Biology.

[21]  M. Shaw.  The host interactome of influenza virus presents new potential targets for antiviral drugs , 2011, Reviews in medical virology.

[22]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[23]  R. König,et al.  Human Host Factors Required for Influenza Virus Replication , 2010, Nature.

[24]  Daniel Becker,et al.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.

[25]  David J. Adams,et al.  The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.

[26]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[27]  C. Viboud,et al.  Mortality and morbidity burden associated with A/H1N1pdm influenza virus , 2009, PLoS currents.

[28]  M. Kinch,et al.  The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. , 2009, Virology.

[29]  M. Newton,et al.  Drosophila RNAi screen identifies host genes important for influenza virus replication , 2008, Nature.

[30]  Guillermo Repetto,et al.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity , 2008, Nature Protocols.

[31]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[32]  Niall Johnson,et al.  Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.

[33]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.

[34]  A. Monto,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. , 1999, The Journal of infectious diseases.

[35]  A Helenius,et al.  Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins , 1996, Journal of virology.

[36]  A Helenius,et al.  Nuclear trafficking of influenza virus ribonuleoproteins in heterokaryons , 1996, Journal of virology.

[37]  D. Wolf,et al.  The Cdc48 machine in endoplasmic reticulum associated protein degradation. , 2012, Biochimica et biophysica acta.

[38]  F Y Aoki,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. , 2000, Lancet.

[39]  D. M. Morgan,et al.  Tetrazolium (MTT) assay for cellular viability and activity. , 1998, Methods in molecular biology.